Amano Enzyme Inc. Overview
Amano Enzyme is a family-led, Nagoya-based specialty enzyme manufacturer with 127 years of corporate history and 78 years of enzyme production. It does not compete in bulk commodity enzymes for detergents, biofuels or feed. Its franchise is high-value microbial enzymes for food processing, digestive health and dietary supplements, diagnostics, regenerative medicine and biocatalysis. It has three Japanese plants, a plant in Jiangsu, China, and a manufacturing and blending site in Elgin, Illinois. It combines traditional koji (solid-state) and liquid fermentation with classical strain screening and modern protein engineering. More than 70% of sales come from outside Japan. R&D spending runs at about 10% of sales, supported by roughly 420 patents and a library of about 20,000 microbial strains. The balance sheet is very strong, with an equity ratio near 89% at March 2024. Disclosure is minimal. Growth rests on plant-based protein enzymes and a 2024 push into non-food industrial applications.
Company's own description. The company describes its business as the manufacture and sale of enzyme agents for the pharmaceutical, food and manufacturing industries and for diagnostic reagents, together with pharmaceuticals, veterinary medicines and feed additives (Company Overview; Sustainability Report 2025). Its recruiting materials divide activity into two fields. The medical field covers pharmaceutical, diagnostic and synthesis enzymes. The food field covers enzymes for dairy, seasonings, alcoholic beverages and baking (Mynavi).
Independent characterisation. Amano is a pure-play specialty enzyme producer and sits mid-value-chain. It sources microbial strains from nature, improves them by classical mutagenesis or, where markets permit, by genetic and protein engineering. It then ferments, purifies, formulates and sells enzyme preparations to industrial customers. It does not sell consumer products. The company once made over-the-counter medicines such as the "Biodiastase" stomach remedy, and it exited that business when it decided in 1996 to specialise in enzymes.
Revenue model. Revenue is almost entirely product sales of enzyme preparations, sold by weight and activity unit to business customers. The company also offers tailor-made enzyme development with customers ("Tailor-Made Solutions" and the "Enzyme Application Studio"). Whether this generates separate service or licensing revenue is not publicly disclosed. There is no evidence of subscription revenue. The product, service and licensing mix is not publicly disclosed.
Value chain position and customers. Customers are food and beverage manufacturers, plant-protein ingredient processors, dietary supplement formulators, over-the-counter drug makers, in-vitro diagnostics manufacturers, cell-therapy and regenerative medicine developers, and fine-chemical and pharmaceutical synthesis operations. Japanese recruiting disclosures state that Amano's digestive enzymes hold the leading share in domestic stomach remedies (Mynavi; Plus-H).
End-markets. The website organises applications under three headings: Food, Healthcare & Medical, and Green Chemistry. A separate microsite, Plants Unlimited, covers plant-based food enzymes. The Sustainability Report 2025 adds prospective fields that the company is exploring: agriculture, energy, materials, textiles and environmental conservation.
Strategy
Stated themes. The corporate philosophy rests on three ideas: Jizen (a spirit of giving and caring), a pioneering spirit, and coexistence. The founder's maxim is rendered as "Making the Intangible, Tangible" (Sustainability Report 2025). The company slogan refers to exploring the unlimited possibilities of enzymes. The 1996 goal of becoming the world's leading specialty enzyme producer remains the reference point.
Initiatives in the last 24 months
Financial targets and guidance. None are published. There is no investor day, medium-term plan or cost programme in the public domain.
Products & Services
Amano's naming convention places "Amano" in quotation marks inside the product name. The first table lists products confirmed in 2021–2026 sources. Pricing is not publicly disclosed for any product.
A. Products verified in recent sources
B.
Services. Tailor-made enzyme development, application support through the Enzyme Application Studio, and regulatory documentation covering Kosher, Halal, vegan and non-GMO status. Commercial terms are not publicly disclosed.
Product Portfolio
| Product | Area | Description and capability | Target customer | Date | Source |
|---|---|---|---|---|---|
ProBoost Neutra | Food, plant-based | Enzyme for pea protein isolate. Improves solubility and emulsification and reduces off-notes while maintaining protein content. Replaces the alkaline step and fits existing wet-fractionation lines. Trade press reports roughly a tripling of solubility. | Pea protein processors | Unveiled 10 June 2026 | Vegconomist; Nutritional Outlook; Food and Drink Technology |
Protein Glutaminase "Amano" 500 (PG500) | Food, plant-based | Protein-deamidating enzyme from Chryseobacterium proteolyticum. Improves protein solubility at low pH and prevents plant milk curdling in coffee, without hydrolysing peptide chains. Positioned for organic and non-GMO products. | Plant-based dairy and beverage makers | Introduced 2023–24 | Company news; Nutraceuticals World; Nutritional Outlook |
Veramax G2 and Veramax G3 | Food, plant-based | Part of the Plants Unlimited toolkit, positioned for sweetness and mouthfeel in plant-based dairy. | Plant-based dairy makers | Featured 2025 | Protein Production Technology |
Umamizyme Pulse | Food, plant-based | Non-GMO enzyme formulation that raises glutamic acid and cysteine in pea, soy, almond and rice proteins. Gives umami and kokumi with less bitterness and works in acidic conditions. | Meat-alternative, soup, broth and snack producers | Launched March 2021 | Food Business News; FoodIngredientsFirst |
Coffee processing enzyme | Food, beverage | Lowers coffee viscosity, raises filtration speed and output for hot and cold brew, without affecting flavour. Product name not disclosed in the source. | Coffee beverage makers | Introduced July 2024 | Nutraceuticals World |
Tea processing enzymes | Food, beverage | Increase aroma, reduce turbidity, improve clarity, colour and yield. | Tea beverage makers | Introduced July 2024 | Nutraceuticals World |
Palatant enzyme portfolio (proteases, lipases, nucleases, deaminases) | Pet food | Applied to umami, aroma and palatability in pet food. Includes work on enzymatically modified animal fats. | Pet food and palatant makers | Presented April 2026 | Petfood Industry |
Collagen peptide enzyme selection framework | Supplements | Protease selection approach for targeted collagen peptide design. | Supplement and nutraceutical formulators | Presented mid-2026 | Nutritional Outlook |
Digestive enzymes (diastase, biodiastase, pancreatin) | Healthcare | Enzymes for stomach remedies and indigestion, produced for about 75 years. Leading share in Japanese stomach medicines. | Drug and supplement makers | Since 1948 | Sustainability Report 2025; Mynavi |
Blood glucose sensor enzymes | Diagnostics | Enzymes that react with blood glucose for monitoring devices. | Diagnostics manufacturers | Since 1970 (diagnostic enzymes) | Sustainability Report 2025 |
Enzymes for regenerative medicine | Medical | Sterile enzymes that improve cell recovery in cell processing. | Cell therapy developers | — | Sustainability Report 2025; OpenWork profile |
Improved lipase for l-menthol | Green Chemistry | Engineered lipase developed with AIST for high-purity l-menthol production; commercialisation as an enzyme preparation was under way. | Flavour and fine-chemical producers | Announced February 2025 | cdmo.jp register |
Cocoa butter alternative lipase application | Food, oils | Enzymatic conversion of palm oil into cocoa butter alternatives. | Fats and oils processors | — | Sustainability Report 2025 |
Anti-staling starch enzymes | Food, starch | Slow starch retrogradation to keep rice and bakery products soft for longer. | Bakery and ready-meal makers | — | Sustainability Report 2025; Nikkei Business |
“—” = not publicly disclosed.
| Product family | Enzyme class | Typical use |
|---|---|---|
Protease M "Amano", Protease A "Amano", Protease P "Amano", Peptidase R, ProteAX, Thermoase | Proteases and peptidases | Protein hydrolysates, seasonings, debittering |
Lipase AY "Amano", Lipase DF "Amano", Lipase MER, Lipase R, Lipase PS "Amano", Lipase AK "Amano" | Lipases | Dairy flavour, oil modification, chiral resolution |
Kleistase, Gluczyme, Biozyme, Beta-amylase F "Amano", Transglucosidase L "Amano" | Amylases and glycosidases | Starch processing, brewing, syrups |
Lactase F "Amano" | Lactase | Dairy digestion supplements |
Hemicellulase "Amano" 90, Cellulase A "Amano", Cellulase T "Amano", Pectinase G "Amano" | Carbohydrases | Fruit, vegetable and extraction processing |
Deamizyme, Glutaminase SD-C100S, Enzyme RP-1G (nuclease) | Flavour enzymes | Yeast extract, umami enhancement |
Financial Narrative
Full financial statements are not public. The parent's Kanpō notice gives a condensed balance sheet and net income. Revenue comes from recruiting disclosures and press. Gross profit, operating income, EBITDA, pre-tax income, earnings per share, dividends, cash flow, capital expenditure, debt split, goodwill and working capital are not publicly disclosed for any year.
Income statement items
Balance sheet items (parent)
Ratios (parent, year-end basis)
Sources and method: FY2024 net income, retained earnings, net assets and total assets are from the 76th-term Kanpō notice published 18 October 2024. FY2023 net income and total assets are derived from year-on-year changes shown by Yahoo! Shigoto Catalog (an aggregator) and are lower confidence. Total liabilities, margins and ratios are calculated from these figures. The R&D ratio is from Mynavi and Nikkei Business.
Commentary.
Revenue: Standalone revenue rose 10.3% from JPY 22.3 billion in FY2024 to JPY 24.6 billion in FY2025. An older data point of JPY 16,935 million for FY2017 (Wikipedia JP) implies a compound annual growth rate of roughly 4.8% over eight years. Group revenue of about JPY 27 billion in FY2025 was described by Nikkei Business as a record. Growth has been helped by overseas demand and, in yen terms, by a weak yen on a sales base that is more than 70% foreign.
Profitability: FY2024 parent net income of JPY 5,278 million equals 23.7% of standalone revenue. That is unusually high and is nearly three times the derived FY2023 figure. The jump coincides with total assets rising from about JPY 40.8 billion to JPY 76.1 billion in one year. An increase of that size cannot come from operating earnings alone. It points to a one-off event such as a group reorganisation, an absorption of an affiliated entity or an asset revaluation. The cause is not publicly disclosed, and FY2024 net income should not be treated as a run-rate. One former subsidiary, Shizuoka Seikagaku K.K., appears in the Kanpō database as closed, but its total assets of about JPY 400 million are far too small to explain the change.
Balance sheet: Net assets of JPY 68.0 billion against liabilities of JPY 8.2 billion give an equity ratio of 89.3%. Retained earnings make up 96% of net assets. The company is, on this evidence, effectively unlevered, although the debt and cash breakdown is not disclosed. Net debt to EBITDA, interest coverage, ROIC and the cash conversion cycle cannot be calculated.
Cash flow and capital allocation: Not publicly disclosed. Visible uses of capital are the Elgin expansion (2024–25) and a minority investment in Chitose Bio Evolution reported by PitchBook in March 2025.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Division Overview
| Division | Head | Title |
|---|---|---|
Innovation Division | Shotaro Yamaguchi | Senior Managing Director and Chief Technology Officer |
Business Development Division | Kazumi Washisaka | Managing Director |
General Affairs Division | Fumikazu Ishikawa | Managing Director |
Production Division | Shigenori Okada | Director |
Quality Assurance Division | Hidetaka Sugimoto | Director |
Accounting & Financial Division | Kunio Hara | Member of Management Council |
Well-being Promotion Division | Chizuru Adachi | Member of Management Council |
Operating Areas
| Area | Contents | Revenue disclosed? |
|---|---|---|
Food | Enzymes for protein, starch, fats and oils, seasonings and flavour, dairy, brewing, baking, beverages, plant-based foods | No |
Healthcare & Medical | Digestive enzymes for medicines and supplements, diagnostic enzymes, enzymes for regenerative medicine | No |
Green Chemistry | Biocatalysts for chiral synthesis and pharmaceutical intermediates | No |
New industrial fields (venture launched 2024) | Agriculture, energy, materials, textiles, environmental uses (exploratory) | No |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Total revenue, parent standalone (JPY Mn) | 22,300 | 24,600 |
Total revenue, group approximate (JPY Mn) | — | 27,000 |
Standalone revenue growth YoY (%) | — | 10.3 |
Income Statement and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Revenue, parent standalone (JPY Mn) | — | 22,300 | 24,600 |
Revenue, group approximate (JPY Mn) | — | — | 27,000 |
Net income, parent (JPY Mn) | 1,828 | 5,278 | — |
Net margin, parent (%) | — | 23.7 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (JPY Mn) | 40,784 | 76,138 | — |
Net assets (JPY Mn) | — | 67,985 | — |
Retained earnings (JPY Mn) | — | 65,471 | — |
Total liabilities, derived (JPY Mn) | — | 8,153 | — |
Paid-in capital (JPY Mn) | 390 | 390 | 390 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
Equity ratio (%) | 89.3 | — |
ROE on year-end equity (%) | 7.8 | — |
ROA on year-end assets (%) | 6.9 | — |
Asset turnover on year-end assets (x) | 0.29 | — |
Liabilities to equity (x) | 0.12 | — |
R&D intensity, approximate (% of sales) | — | 10 |
Revenue by Region (%) and Revenue by Region
| Metric | FY2025 |
|---|---|
Overseas share of sales, minimum (%) | 70 |
Japan share of sales, maximum (%) | 30 |
Implied overseas sales on group revenue, minimum (JPY Mn) | 18,900 |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1, 3, 5 years) | Not applicable; shares are not traded |
Analyst consensus | None; no coverage |
Credit ratings (Moody's, S&P, Fitch) | None found |
Debt maturity profile | Not publicly disclosed; total liabilities were JPY 8,153 million at March 2024 |
External funding history | None; aggregators record no fundraising |
Analyst Conclusions
Guidance and consensus. The company publishes no guidance and there is no consensus. The only forward commitments are the 2030 environmental targets.
Bull case
-
Proprietary enzymes address real formulation problems in a growing category. PG500 and ProBoost Neutra target solubility and off-flavour in plant proteins, and the latter fits existing processing lines.
-
Financial capacity is ample. An equity ratio near 89% lets the company fund capacity, R&D at 10% of sales and minority investments without external capital.
-
Momentum is positive. Standalone sales grew 10.3% in FY2025, group sales reached a record, and the US site has been enlarged.
Bear case
-
Scale disadvantage is widening as Novonesis grows 7% organically from a base about twenty times larger and invests over EUR 400 million a year in R&D.
-
Reported growth may flatter underlying performance, because a weak yen inflates overseas sales and the FY2024 profit appears to contain a one-off.
-
Opacity and insider-only governance limit external scrutiny and leave succession and capital allocation unexamined.
Catalysts and monitorables for the next 12 months
-
Kanpō notice for the year to March 2026, and any updated sales figure in recruiting disclosures.
-
Commercial adoption of ProBoost Neutra by pea-protein processors.
-
Evidence of revenue from the 2024 industrial-enzyme venture.
-
Yen movements against the dollar and euro.
-
Progress data on emissions in the next Environment Report.
-
Any explanation of the FY2024 asset increase, and any change in group structure.
-
Further minority investments or partnerships following Chitose.
Analyst verdict. Amano Enzyme is a well-capitalised specialist that has chosen depth over breadth. Its 1996 decision to abandon pharmaceuticals and concentrate on enzymes has produced a business with group sales of about JPY 27 billion, more than 70% of them overseas, and a balance sheet that carries almost no liabilities. The technical franchise is credible. It rests on a large strain library, a patent estate of about 420, sustained R&D spending near 10% of sales, and a rare combination of koji and liquid fermentation skills. Recent launches show that the company can identify specific customer problems and solve them with distinctive enzymes.
The limits are equally clear. Amano is small in an industry that is consolidating around a few global groups, and its newest products lean on plant-based foods, a category with uneven demand. Its absolute emissions are moving the wrong way against a stretching 2030 target. Above all, it discloses very little. Operating profit, cash flow, segment mix and ownership are all unknown, and the one published profit figure for FY2024 appears distorted by an unexplained event that nearly doubled total assets. Governance is that of a family firm, with a board made up entirely of executives.
For a counterparty, supplier or partner, the evidence supports a view of Amano as financially robust, technically strong and strategically consistent. For anyone attempting valuation or credit analysis, the public record is insufficient, and direct engagement with the company would be required. The most informative near-term signals will be the next statutory notice, uptake of ProBoost Neutra, and any sign that the 2024 move into industrial applications is generating revenue.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Motoyuki Amano | President (Representative Director) | Member of the founding family. The company history lists Motohiro Amano as President until 1995; the exact start date of the current President's tenure is not explicitly stated. |
Shotaro Yamaguchi | Senior Managing Director; Head of Innovation Division; CTO | — |
Kazumi Washisaka | Managing Director; Head of Business Development Division | — |
Fumikazu Ishikawa | Managing Director; Head of General Affairs Division | — |
Shigenori Okada | Director; Head of Production Division | — |
Hidetaka Sugimoto | Director; Head of Quality Assurance Division | — |
Motonari Amano | Director; Deputy Head of Business Development Division | Shares the founding family surname; relationship not publicly stated |
Yasuhiro Nomura | Full-time Auditor | Statutory corporate auditor |
Makoto Kamiya | Part-time Auditor | Statutory corporate auditor |
Kunio Hara | Management Council; Head of Accounting & Financial Division | — |
Toshihisa Toyomasu | Management Council; Deputy Head of Innovation Division | — |
Chizuru Adachi | Management Council; Head of Well-being Promotion Division | — |
Competitive Landscape
Key Competitors
| Competitor | Home | Overlap with Amano | Scale indicator |
|---|---|---|---|
Novonesis (Novozymes and Chr. Hansen) | Denmark | Food enzymes, plant-based, human health | 2025 sales of roughly EUR 4.2 billion (derived from reported adjusted EBITDA and margin) |
dsm-firmenich | Switzerland/Netherlands | Food and beverage enzymes, lactase | — |
IFF (Health & Biosciences) | USA | Food enzymes, health | — |
Kerry Group (biotechnology solutions) | Ireland | Food enzymes, proteases | — |
AB Enzymes (Associated British Foods) | Germany | Baking and food enzymes | — |
Advanced Enzyme Technologies | India | Digestive and supplement enzymes | — |
Ajinomoto | Japan | Transglutaminase for food texture | — |
Nagase Group (Nagase Viita, Nagase ChemteX) | Japan | Food and industrial enzymes | — |
Shin Nihon Chemical | Japan | Food enzymes | — |
HBI Enzymes | Japan | Food enzymes | — |
Biocatalysts Ltd | UK | Specialty food enzymes, custom development | — |
Toyobo, Kikkoman Biochemifa | Japan | Diagnostic enzymes | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Amano Enzyme (FY2025) | Novonesis (2025) |
|---|---|---|
Revenue | about JPY 27 billion group | about EUR 4.2 billion (derived) |
Growth | 10.3% (standalone, reported) | 7% organic |
EBITDA margin | — | 37.1% adjusted |
R&D intensity | about 10% of sales | above EUR 400 million a year, roughly 10% of sales |
“—” = not publicly disclosed.
Recent Developments
The company issues few announcements. One slightly earlier item is included for context.
